scholarly journals The Effect of Topical Corticosteroid Time of Application on Fibroblast and Type III Collagen Expression in Oryctolagus cuniculus with Deep Dermal Burn Wound (As an Indicator for the Best Time to Start Topical Corticosteroid Application in Preventing Hypertrophic Scar)

2021 ◽  
Vol 9 (B) ◽  
pp. 964-970
Author(s):  
Loelita Lumintang ◽  
I Made Suka Adnyana ◽  
Agus Roy Hamid ◽  
Hendra Sanjaya ◽  
Nyoman Golden ◽  
...  
Keyword(s):  
Treatment Group ◽  
Hypertrophic Scar ◽  
Type Iii Collagen ◽  
Hypertrophic Scars ◽  
Burn Wound ◽  
Type Iii ◽  
The Third ◽  
Topical Corticosteroids ◽  
Collagen Expression ◽  
Phase Group

Background: Hypertrophic scar is an abnormal scar that causes physical deteriorations, psychological problems, and aesthetic issues. An excessive number of fibroblasts and collagen III expressions are histopathology indicators for the hypertrophic scar. The role of topical corticosteroids in suppressing inflammation and hypergranulation had widely demonstrated in previous studies. However, there is no study related to the application of topical corticosteroids as prevention of hypertrophic scars from burn wound found. Hence, this study aimed to examine the evidence of the effects of corticosteroid topical in decreasing the number of fibroblasts and type III collagen expression and the best time to start its application in preventing hypertrophic scars. Methods: This randomized experimental post-test only study involved 54 deep dermal burn wounds on the ventral ear of female Oryctolagus cuniculus that distributed into three groups based on the healing phases. Each group consisted of treatments and controls. Corticosteroid topical application on the first treatment group (inflammatory phase group), the second group (proliferation phase group), and the third group (remodelling phase group) was started on day 3, on day 10, and day 21, respectively. Specimens taken on day 35. Haematoxylin-Eosin and Immunohistochemically staining performed to measure the number of fibroblasts and type III collagen and to observe the epithelization and inflammation process. Results: The number of fibroblasts significantly decreased in the second treatment group (p =0.001) and followed by the first group (p = 0.016), but no significant decrease found in the third group (p = 0.430). The type III collagen decreased significantly in the second treatment group (p = 0.000) and followed by the third group (p = 0.019), but no significant decrease found in the first group. There was no statistically different number of fibroblast and type III collagen discovered between the controls. Complete epithelization found in all groups. Also, no ongoing inflammation found in all groups.  Conclusion : Topical corticosteroids on deep dermal burn wound revealed to be effective in reducing the number of fibroblasts and type III collagen with no healing disruption. The proliferation phase found to be the best time to start the application of topical corticosteroids.

scholarly journals Basic fibroblast growth factor modulates proliferation and collagen expression in urinary bladder smooth muscle cells

2007 ◽  
Vol 293 (4) ◽  
pp. F1007-F1017 ◽  
Author(s):  
Masaaki Imamura ◽  
Akihiro Kanematsu ◽  
Shingo Yamamoto ◽  
Yu Kimura ◽  
Isao Kanatani ◽  
...  
Keyword(s):  
Smooth Muscle ◽  
Type I Collagen ◽  
Type Iii Collagen ◽  
Type I ◽  
Fibroblast Growth ◽  
Bladder Smooth Muscle ◽  
Type Iii ◽  
Collagen Expression

Bladder hypertrophy is a general consequence of bladder outlet obstruction (BOO) and a typical phenomenon observed in clinical urologic diseases such as benign prostatic hyperplasia and neurogenic bladder. It is characterized by smooth muscle hyperplasia, altered extracellular matrix composition, and increased contractile function. Various growth factors are likely involved in hypertrophic pathophysiology, but their functions remain unknown. In this report, the role of basic fibroblast growth factor (bFGF) was investigated using a rat bladder smooth muscle cell (BSMC) culture system and an original animal model, in which bFGF was released from a gelatin hydrogel directly onto rat bladders. bFGF treatment promoted BSMC proliferation both in vitro and in vivo. In vitro, bFGF downregulated the expression of type I collagen, but upregulated type III collagen. ERK1/2, but not p38MAPK, was activated by bFGF, whereas inhibition of ERK1/2 by PD98059 reversed bFGF-induced BSMC proliferation, type I collagen downregulation, and type III collagen upregulation. In the in vivo release model, bFGF upregulated type III collagen and increased the contractile force of treated bladders. In parallel with these findings, hypertrophied rat bladders created by urethral constriction showed increased urothelial bFGF expression, BSMC proliferation, and increased type III collagen expression compared with sham-operated rats. These data suggest that bFGF from the urothelium could act as a paracrine signal that stimulates the proliferation and matrix production of BSMC, thereby contributing to the hypertrophic remodeling of the smooth muscle layer.

scholarly journals Bioflavonoid Galangin Suppresses Hypertrophic Scar Formation by the TGF-β/Smad Signaling Pathway

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Zha Ru ◽  
Ying Hu ◽  
Shenghua Huang ◽  
Li Bai ◽  
Kun Zhang ◽  
...  
Keyword(s):  
Signaling Pathway ◽  
Hypertrophic Scar ◽  
Healing Process ◽  
Scar Formation ◽  
Type Iii Collagen ◽  
Type I ◽  
Smad Signaling ◽  
Type Iii ◽  
Smad Signaling Pathway ◽  
Tgf Β1

Background. Hypertrophic scar (HS) is a benign fibroproliferative skin disease resulting from an aberrant wound healing process and can cause aesthetic and functional damage to patients. Currently, there is no ideal treatment to treat this disease. Galangin, a natural active bioflavonoid compound, is suggested to inhibit fibrosis and proliferation in certain cells. Methods. In this study, we found Galangin could attenuate abnormal scar formation in an HS rabbit ear model. Additionally, the HE staining shows Galangin reduced scar elevation index (SEI) and Masson’s trichrome staining changed collagen deposition. Results. The expressions of type I collagen, type III collagen, and TGF-β1 were much lower under a proper dose of Galangin treatment, and Smad7 expression was also enhanced, which are examined by real-time PCR, immunohistochemistry, and western blot. Conclusion. Our data indicated that Galangin can alleviate dermal scarring via the TGF-β/Smad signaling pathway probably by upregulating Smad 7 expression and, thus, suppressing the expression of type I and type III collagens and TGF-β1.

Airway remodeling-associated mediators in moderate to severe asthma: Effect of steroids on TGF-β, IL-11, IL-17, and type I and type III collagen expression

2003 ◽  
Vol 111 (6) ◽  
pp. 1293-1298 ◽  
Author(s):  
Jamila Chakir ◽  
Joanne Shannon ◽  
Sophie Molet ◽  
Motonori Fukakusa ◽  
Jack Elias ◽  
...  
Keyword(s):  
Severe Asthma ◽  
Airway Remodeling ◽  
Type Iii Collagen ◽  
Type I ◽  
Type Iii ◽  
Collagen Expression

Immunohistochemical analysis of type III collagen expression in the lingual mucosa of rats during organogenesis of the tongue

Odontology ◽  
2008 ◽  
Vol 96 (1) ◽  
pp. 12-20 ◽  
Author(s):  
Shin-ichi Iwasaki ◽  
Tomoichiro Asami ◽  
Chaitip Wanichanon ◽  
Hideki Yoshizawa ◽  
Hidekazu Aoyagi
Keyword(s):  
Immunohistochemical Analysis ◽  
Type Iii Collagen ◽  
Type Iii ◽  
Collagen Expression ◽  
Lingual Mucosa

scholarly journals A prospective study of time to healing and hypertrophic scarring in paediatric burns: every day counts

2017 ◽  
Vol 5 ◽  
Author(s):  
Elizabeth Chipp ◽  
Lisa Charles ◽  
Clare Thomas ◽  
Kate Whiting ◽  
Naiem Moiemen ◽  
...  
Keyword(s):  
Prospective Study ◽  
Hypertrophic Scar ◽  
Statistical Significance ◽  
Hypertrophic Scars ◽  
Hypertrophic Scarring ◽  
Burn Wound ◽  
White Skin ◽  
Scar Assessment ◽  
Paediatric Burns ◽  
A Prospective Study

Abstract Background It is commonly accepted that burns taking longer than 3 weeks to heal have a much higher rate of hypertrophic scarring than those which heal more quickly. However, some of our patients develop hypertrophic scars despite healing within this 3-week period. Methods We performed a prospective study of 383 paediatric burns treated non-operatively at a regional burns centre over a 2-year period from May 2011 to April 2013. Scar assessment was performed by a senior burns therapist using the Vancouver Scar Scale. Results Overall rates of hypertrophic scarring were 17.2%. Time to healing was the strongest predictor of developing hypertrophic scarring, and the earliest hypertrophic scar developed in a patient who was healed after 8 days. The risk of hypertrophic scarring was multiplied by 1.138 for every additional day taken for the burn wound to heal. There was a trend towards higher rates of hypertrophic scarring in non-white skin types but this did not reach statistical significance. Conclusions The risk of hypertrophic scarring increases with every day and, therefore, every effort should be made to get the wound healed as quickly as possible, even within the traditional 3-week period usually allowed for healing. We believe that the traditional dogma of aiming for healing within 3 weeks is overly simplistic and should be abandoned: in paediatric burns, every day counts. Trial registration Not applicable.

Sign in / Sign up

Export Citation Format

Share Document